These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38022586)

  • 41. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
    Davis KL; Gray ES; Moore PL; Decker JM; Salomon A; Montefiori DC; Graham BS; Keefer MC; Pinter A; Morris L; Hahn BH; Shaw GM
    Virology; 2009 May; 387(2):414-26. PubMed ID: 19298995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
    Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
    Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
    Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies.
    Fouda GG; Yates NL; Pollara J; Shen X; Overman GR; Mahlokozera T; Wilks AB; Kang HH; Salazar-Gonzalez JF; Salazar MG; Kalilani L; Meshnick SR; Hahn BH; Shaw GM; Lovingood RV; Denny TN; Haynes B; Letvin NL; Ferrari G; Montefiori DC; Tomaras GD; Permar SR;
    J Virol; 2011 Sep; 85(18):9555-67. PubMed ID: 21734046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers.
    Yang Z; Dam KA; Gershoni JM; Zolla-Pazner S; Bjorkman PJ
    J Virol; 2022 Dec; 96(24):e0108222. PubMed ID: 36448805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study.
    Perdiguero B; Asbach B; Gómez CE; Köstler J; Barnett SW; Koutsoukos M; Weiss DE; Cristillo AD; Foulds KE; Roederer M; Montefiori DC; Yates NL; Ferrari G; Shen X; Sawant S; Tomaras GD; Sato A; Fulp WJ; Gottardo R; Ding S; Heeney JL; Pantaleo G; Esteban M; Wagner R
    Front Immunol; 2022; 13():939627. PubMed ID: 35935978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
    Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
    J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early Post-Vaccination Gene Signatures Correlate With the Magnitude and Function of Vaccine-Induced HIV Envelope-Specific Plasma Antibodies in Infant Rhesus Macaques.
    Vijayan KKV; Cross KA; Curtis AD; Van Rompay KKA; Pollara J; Fox CB; Tomai M; Hanke T; Fouda G; Hudgens MG; Permar SR; De Paris K
    Front Immunol; 2022; 13():840976. PubMed ID: 35572573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins.
    Yuan T; Li J; Zhang MY
    MAbs; 2011; 3(4):402-7. PubMed ID: 21540646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
    Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
    Spearman P; Lally MA; Elizaga M; Montefiori D; Tomaras GD; McElrath MJ; Hural J; De Rosa SC; Sato A; Huang Y; Frey SE; Sato P; Donnelly J; Barnett S; Corey LJ;
    J Infect Dis; 2011 Apr; 203(8):1165-73. PubMed ID: 21451004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?
    Alexander MR; Ringe R; Sanders RW; Voss JE; Moore JP; Klasse PJ
    J Virol; 2015 Jun; 89(11):5981-95. PubMed ID: 25810537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
    von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
    J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth.
    Li Y; Bai H; Sanders-Buell E; Dussupt V; Townsley S; Donofrio G; Bose M; O'Sullivan AM; Kibuuka H; Maganga L; Nitayaphan S; Kosgei J; Pitisuttithum P; Rerks-Ngarm S; Eller LA; Michael NL; Robb ML; Ake J; Vasan S; Tovanabutra S; Krebs SJ; Rolland M
    J Virol; 2021 Aug; 95(17):e0079721. PubMed ID: 34160251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation.
    Chen JL; Fries CN; Berendam SJ; Rodgers NS; Roe EF; Wu Y; Li SH; Jain R; Watts B; Eudailey J; Barfield R; Chan C; Moody MA; Saunders KO; Pollara J; Permar SR; Collier JH; Fouda GG
    Sci Adv; 2022 Sep; 8(38):eabq0273. PubMed ID: 36149967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Corrigendum: Pediatric Burn Survivors Have Long-Term Immune Dysfunction With Diminished Vaccine Response.
    Johnson BZ; McAlister S; McGuire HM; Palanivelu V; Stevenson A; Richmond P; Palmer DJ; Metcalfe J; Prescott SL; Wood FM; Fazekas de St Groth B; Linden MD; Fear MW; Fear VS
    Front Immunol; 2020; 11():598646. PubMed ID: 33163008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.